Biohaven earns preventative nod for migraine med Nurtec, snaring a much-needed leg up over AbbVie

Biohaven had a rough start to the year with failing data in Alzheimer’s that sent investor interest spinning out. But the drugmaker still had a lot of reason to believe in CGRP migraine med Nurtec despite a big challenge from AbbVie — and now that belief is continuing to pay off.